Drugs / Wharton's jelly-derived mesenchymal stem cells
Wharton's jelly-derived mesenchymal stem cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07018739 | Sep 2026 → Dec 2032 expected | brain hypoxia - ischemia | Mahidol University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04390152 | Jan 2020 → Mar 2022 | acute respiratory distress syndrome | BioXcellerator | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05800301 Comparator | Jan 2019 → Dec 2021 | retinitis pigmentosa | Ankara University Technopolis | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Wharton's jelly-derived mesenchymal stem cells | “Wharton's jelly-derived mesenchymal stem cells implanted in sub-tenon space have beneficial effects” PMID 31931872 ↗ Jan 2020 |
| Known as | Mesenchymal stem cells | “Mesenchymal stem cells (MSC) have shown great immunomodulatory effects” NCT04390152 ↗ |
| Known as | MSC | “Mesenchymal stem cells (MSC) have shown great immunomodulatory effects” NCT04390152 ↗ |
| Modality | Cell therapy | “umbilical cord Wharton's jelly derived mesenchymal stem cells” PMID 31931872 ↗ Jan 2020 |
| Route | Intravenous | “IV Wharton's jelly derived Mesenchymal stem cells, two doses” NCT04390152 ↗ |